Zhende Medical Co., Ltd.
SSE:603301.SS
20.83 (CNY) • At close June 6, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 4,263.886 | 4,127.044 | 6,137.634 | 5,091.572 | 10,398.546 | 1,867.728 | 1,428.857 | 1,306.443 | 1,034.899 | 1,021.012 | 986.915 |
| Cost of Revenue
| 2,813.364 | 2,850.402 | 3,991.505 | 3,319.139 | 5,514.701 | 1,268.821 | 980.73 | 919.904 | 706.887 | 715.759 | 768.366 |
| Gross Profit
| 1,450.522 | 1,276.642 | 2,146.129 | 1,772.434 | 4,883.845 | 598.907 | 448.127 | 386.538 | 328.013 | 305.254 | 218.549 |
| Gross Profit Ratio
| 0.34 | 0.309 | 0.35 | 0.348 | 0.47 | 0.321 | 0.314 | 0.296 | 0.317 | 0.299 | 0.221 |
| Reseach & Development Expenses
| 135.49 | 138.947 | 227.003 | 153.141 | 259.713 | 50.954 | 56.913 | 43.657 | 31.103 | 32.33 | 31.745 |
| General & Administrative Expenses
| 125.066 | 508.82 | 140.356 | 146.563 | 135.489 | 50.657 | 28.879 | 21.29 | 35.231 | 30.887 | 101.9 |
| Selling & Marketing Expenses
| 190.819 | 199.297 | 476.962 | 366.756 | 492.474 | 187.91 | 117.798 | 89.319 | 77.43 | 68.84 | 45.045 |
| SG&A
| 315.885 | 896.244 | 617.319 | 513.319 | 627.963 | 238.567 | 146.677 | 110.609 | 112.661 | 99.727 | 146.946 |
| Other Expenses
| 507.352 | 15.503 | 318.174 | 252.737 | 246.524 | 73.184 | -1.86 | -0.643 | 20.46 | 8.805 | 9.65 |
| Operating Expenses
| 958.726 | 1,050.694 | 1,162.495 | 919.198 | 1,134.199 | 362.705 | 267.257 | 210.277 | 228.577 | 206.931 | 152.501 |
| Operating Income
| 491.796 | 225.948 | 812.81 | 821.973 | 3,537.011 | 200.333 | 153.418 | 148.002 | 79.175 | 82.491 | 16.323 |
| Operating Income Ratio
| 0.115 | 0.055 | 0.132 | 0.161 | 0.34 | 0.107 | 0.107 | 0.113 | 0.077 | 0.081 | 0.017 |
| Total Other Income Expenses Net
| -16.337 | -7.056 | -11.094 | -2.024 | -3.924 | -1.096 | -1.86 | -0.643 | 20.46 | 8.805 | 7.975 |
| Income Before Tax
| 475.459 | 218.892 | 801.716 | 819.949 | 3,533.087 | 199.237 | 151.557 | 147.359 | 99.635 | 91.296 | 24.298 |
| Income Before Tax Ratio
| 0.112 | 0.053 | 0.131 | 0.161 | 0.34 | 0.107 | 0.106 | 0.113 | 0.096 | 0.089 | 0.025 |
| Income Tax Expense
| 78.248 | 5.492 | 98.704 | 99.002 | 561.187 | 22.652 | 21.678 | 25.245 | 16.752 | 12.047 | 2.311 |
| Net Income
| 385.171 | 198.399 | 679.878 | 595.862 | 2,549.453 | 156.89 | 130.204 | 121.769 | 82.842 | 79.059 | 21.775 |
| Net Income Ratio
| 0.09 | 0.048 | 0.111 | 0.117 | 0.245 | 0.084 | 0.091 | 0.093 | 0.08 | 0.077 | 0.022 |
| EPS
| 1.45 | 0.74 | 2.87 | 2.64 | 12.5 | 0.8 | 0.72 | 0.83 | 0.57 | 0.6 | 0.59 |
| EPS Diluted
| 1.45 | 0.74 | 2.87 | 2.63 | 12.5 | 0.8 | 0.72 | 0.83 | 0.57 | 0.6 | 0.59 |
| EBITDA
| 750.715 | 490.79 | 1,033.811 | 990.449 | 3,629.976 | 295.197 | 238.579 | 230.575 | 176.979 | 177.356 | 66.047 |
| EBITDA Ratio
| 0.176 | 0.119 | 0.168 | 0.195 | 0.349 | 0.158 | 0.167 | 0.176 | 0.171 | 0.174 | 0.067 |